Lv21
160 积分 2023-07-20 加入
Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)
42分钟前
求助中
Cytokine storm
10小时前
已完结
JAK inhibitor selectivity: new opportunities, better drugs?
5天前
已完结
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
27天前
已完结
Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions
27天前
已完结
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
1个月前
已完结
How I treat anemia in myelofibrosis
2个月前
已完结
Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT
2个月前
已完结
Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation
2个月前
已完结
Optimal GVHD Prophylaxis
3个月前
已完结
皖公网安备34019202002308
